{"Symbol": "ONCY", "AssetType": "Common Stock", "Name": "Oncolytics Biotech Inc", "Description": "Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an immuno-oncology viral-agent for the treatment of solid tumors and hematological malignancies. The company has collaboration agreements with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone-receptor positive, human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. Oncolytics Biotech Inc. was founded in 1998 and is headquartered in Calgary, Canada.", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "Healthcare", "Industry": "Biotechnology", "Address": "1167 Kensington Crescent NW, Calgary, AB, Canada, T2N 1X7", "FullTimeEmployees": "0", "FiscalYearEnd": "December", "LatestQuarter": "2020-06-30", "MarketCapitalization": "71807120", "EBITDA": "None", "PERatio": "None", "PEGRatio": "None", "BookValue": "0.402", "DividendPerShare": "None", "DividendYield": "0", "EPS": "-0.825", "RevenuePerShareTTM": "0", "ProfitMargin": "0", "OperatingMarginTTM": "0", "ReturnOnAssetsTTM": "-0.5438", "ReturnOnEquityTTM": "-2.1138", "RevenueTTM": "0", "GrossProfitTTM": "0", "DilutedEPSTTM": "-0.825", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "0", "AnalystTargetPrice": "None", "TrailingPE": "0", "ForwardPE": "0", "PriceToSalesRatioTTM": "0", "PriceToBookRatio": "4.0247", "EVToRevenue": "0", "EVToEBITDA": "0", "Beta": "1.6759", "52WeekHigh": "6.02", "52WeekLow": "0.351", "50DayMovingAverage": "1.9053", "200DayMovingAverage": "1.8988", "SharesOutstanding": "41657000", "SharesFloat": "40971324", "SharesShort": "1953828", "SharesShortPriorMonth": "1920417", "ShortRatio": "3.22", "ShortPercentOutstanding": "0.05", "ShortPercentFloat": "0.051", "PercentInsiders": "1.384", "PercentInstitutions": "1.398", "ForwardAnnualDividendRate": "0", "ForwardAnnualDividendYield": "0", "PayoutRatio": "0", "DividendDate": "None", "ExDividendDate": "None", "LastSplitFactor": "10:95", "LastSplitDate": "2018-05-25"}